



Cover image: part of "Die drei Lebensalter der Frau", Gustav Klimt, 1905, National Gallery of Modern Art, Rome.

### Preface

- iii1 Advances in targeted therapies IX F C Breedveld, J R Kalden, J S Smolen

### Consensus statement

- iii2 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, P L C M van Riel, R Fleischmann, M H Weisman, M E Weinblatt

### Opening lectures

- iii23 Actin cytoskeleton dynamics linked to synovial fibroblast activation as a novel pathogenic principle in TNF-driven arthritis Y Vasilopoulos, V Gkretsi, M Armaka, V Aidinis, G Kollias  
iii29 New therapies for sepsis: focus on the interleukin (IL)12 family member IL27 M F Neurath  
iii32 Interpreting measurements of physical function in clinical trials M M Ward  
iii35 Thoughts on health economics in rheumatoid arthritis G Kobelt

### Looking at clinical trials and more

- iii40 Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean? T K Kvien, T Heiberg, K B Hagen  
iii42 Joint remodelling in inflammatory disease G Schett

### Animal models

- iii45 Amplifying elements of arthritis and joint destruction W B van den Berg, P L van Lent, L A B Joosten, S Abdollahi-Roodsaz, M I Koenders

### Novel targets I

- iii49 Schnurri-3 is an essential regulator of osteoblast function and adult bone mass D C Jones, M N Wein, L H Glimcher  
iii52  $\alpha$ -MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs T A Luger, T Brzoska

### Insights from investigator-driven trials and genetics

- iii56 Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility M F Bakker,



[www.publicationethics.org.uk](http://www.publicationethics.org.uk)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

*J W G Jacobs, S M M Verstappen,  
J W J Bijlsma*

## The lupus connection

- iii61 Disease activity assessment in SLE: do we have the right instruments? *M Petri*
- iii65 Systemic lupus erythematosus: new molecular targets *J C Crispín, V C Kyttaş, Y-T Juang, G C Tsokos*

## Novel targets II

- iii70 Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy *E Gonzalez-Rey, P Anderson, M Delgado*

- iii77 Update on toll-like receptor-directed therapies for human disease *K Tse, A A Horner*

- iii81 Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue *S M Sacre, S K Drexler, E Andreakos, M Feldmann, F M Brennan, B M J Foxwell*

## Novel targets III

- iii87 Interplay between pathogenic Th17 and regulatory T cells *M Oukka*
- iii91 Regulatory T cells and toll-like receptors: regulating the regulators *R Suttmüller, A Garritsen, G J Adema*